



# Rights Issue Investor Presentation

7 August 2019

Regeneus Ltd (ASX:RGS)

# IMPORTANT NOTICE AND DISCLAIMER

**Overview:** This investor presentation (“Presentation”) has been prepared by Regeneus Ltd (“Regeneus” or “Company”) and is dated 1 August 2019. This Presentation has been prepared in relation to a placement and entitlement offer of new Regeneus ordinary shares (“New Shares”) (“Offers”).

**Summary Information:** This Presentation contains summary information about the current activities of Regeneus as at the date of this Presentation. The information in this Presentation is of a general nature and does not purport to be complete. This Presentation does not purport to contain all the information that an investor should consider when making an investment decision nor does it contain all the information which would be required in a disclosure document or prospectus prepared in accordance with the requirements of the Corporations Act. It should be read in conjunction with Regeneus’ other periodic and continuous disclosure announcements lodged with the ASX, which are available at [www.asx.com.au](http://www.asx.com.au). Neither Regeneus nor its directors, employees or advisers give any warranties in relation to the statements and information in this Presentation.

**Not an offer:** This Presentation is for information purposes only and is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or any other law (and will not be lodged with ASIC or any other regulator and is not approved by or registered with any regulator). The Presentation is not and should not be considered an offer or an invitation to acquire New Shares or any other financial products. This Presentation may not be released or distributed in the United States. This Presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or in any other jurisdiction in which such an offer would be illegal. The New Shares have not been, and will not be, registered under the U.S. Securities Act or the securities laws of any state or other jurisdiction of the United States. Accordingly, the New Shares may not be offered or sold, directly or indirectly, in the United States unless such New Shares have been registered under the U.S. Securities Act, or are offered and sold in a transaction exempt from, or not subject to, the registration requirements of the Securities Act and applicable U.S. state securities laws. The distribution of this Presentation in other jurisdictions outside Australia may also be restricted by law and any such restrictions should be observed. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.

**Not financial product advice:** This Presentation does not constitute financial product or investment advice (nor tax, accounting or legal advice) nor is it a recommendation to acquire New Shares and does not and will not form any part of any contract for the acquisition of New Shares. This Presentation has been prepared without taking into account the objectives, financial situation or needs of any particular investor. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs and seek appropriate advice, including financial, legal and taxation advice appropriate to their jurisdiction. Regeneus is not licensed to provide financial product advice in respect of Regeneus’ shares or any other investment. Cooling off rights do not apply to the acquisition of New Shares.

**Financial data:** All dollar values are in Australian dollars (“A\$”). Any pro forma financial information included in this Presentation is for illustrative purposes only and is not represented as being indicative of Regeneus’ views on its future financial condition and/or performance. Any pro forma financial information has been prepared by Regeneus and may not have been prepared in accordance with the measurement and recognition requirements or the disclosure requirements, of applicable accounting standards and other mandatory requirements in Australia.

**Future performance:** This Presentation contains certain “forward looking statements”. Forward looking statements can generally be identified by the use of forward looking words such as, “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target” “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of Regeneus, the outcome and effects of the Offers and the use of proceeds.

The forward looking statements contained in this Presentation are not guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Regeneus, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. Refer to the risks section of this Presentation for a summary of certain general and Regeneus specific risk factors that may affect Regeneus. There can be no assurance that actual outcomes will not differ materially from these forward-looking statements. A number of important factors could cause actual results or performance to differ materially from the forward looking statements, including the risk factors set out in this Presentation. Investors should consider the forward looking statements contained in this Presentation in light of those disclosures. The forward looking statements are based on information available to Regeneus as at the date of this Presentation. Except as required by law or regulation (including the ASX Listing Rules), Regeneus undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward looking statements.

**Effect of rounding:** A number of figures, amounts, percentages, estimates, calculations of value and fractions in this Presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this Presentation.

**Investment risks:** An investment in New Shares is subject to investment and other known and unknown risks, some of which are beyond the control of Regeneus including possible loss of income and principal invested. Regeneus does not guarantee any particular rate of return or the performance of Regeneus, nor does it guarantee the repayment of capital from Regeneus or any particular tax treatment. In considering an investment in Regeneus shares, investors should have regard to (amongst other things) the risks outlined in this Presentation.

**Disclaimer:** To the maximum extent permitted by law, no representation or warranty, express or implied, is made as to the currency, accuracy, reliability or completeness of information in this Presentation and Regeneus and its advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents excludes and disclaims all liability, including without limitation for negligence or for any expenses, losses, damages or costs incurred by you as a result of your participation in the Offer and the information in this Presentation being inaccurate or incomplete in any way for any reason, whether by negligence or otherwise. Regeneus and its advisors make no recommendations as to whether investors or their related parties should participate in the Offers. Statements made in this Presentation are made only as at the date of this Presentation. The information in this Presentation remains subject to change without notice. Regeneus reserves the right to withdraw all or part of the Offers or vary the timetable for the Offers without notice.

# Terms of Offer


- Partially underwritten 1 for 6 pro rata non-renounceable entitlement offer of new shares in Regeneus at an offer price of \$0.08 per New Share
- Offer open date 13 August 2019
- Entitlement Offer closes at 5.00pm (Sydney time) on 27 August 2019

# Use of Funds


<b>Costs associated with 'Revised Strategic Focus'</b>	<b>\$500k</b>
Ongoing working capital to facilitate Progenza Phase 2 development, including R&D	\$3,600k

- Capital Preservation - Focus Pipeline on Commercialization and Platform Development (shots-on-goal) through scientific collaboration
- Optimize cost base to create runway to commercialization
- Further monetize our assets through BD (regional deals and divestments)
- IR strategy to reflect deal value in RGS and sustain consistent news flow

# Driving Shareholder Value with Consistent News Flow



# Prioritize High Value Assets to Commercialization; Platform Development Through Scientific Partnerships



# Portfolio - Therapeutic Candidates


Program	Technology	Funding Plan	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Filing	Approval
Progenza™	Allogeneic Adipose MSC plus MSC Secretions with Bioactive Molecules & Exosomes*	Focus	Osteoarthritis of Knee						
		Collaboration	Neuropathic Pain						
		Collaboration	Other Indications						
Sygenus™	Allogeneic Adipose MSC Secretions with Bioactive Molecules & Exosomes	Collaboration	Burns, Wounds, Radiodermatitis						
		Collaboration	Neuropathic Pain						
		Collaboration	Psoriasis, Atopic Dermatitis						
		Collaboration	Rare/Orphan Skin Diseases						
RGSH4K	Autologous Cancer Vaccine Immunotherapy	Sell / License out	Solid Tumors						

\* MSC secretions contain: Cytokines, chemokines, growth factors, extracellular vesicles – exosomes, microRNAs, microvesicles



# Patent Portfolio Update

100+ Patents or Patent Applications  
across 14 Patent Families




## Key patents granted

- Patent granted or allowed in US, Europe, Australia, NZ and Japan covering Progenza technology – “*allogeneic stem cells and secretions for the treatment of osteoarthritis and other inflammatory conditions in humans and animals*”
- Patent granted in EU, USA, Australia, Japan and China covering Sygenus stem cell secretions for topical treatment of acne

## Patents cover:

- methods of manufacture
- compositions and delivery
- use of products for treatment of a broad range of indications

## Global Data estimates for Prevalent Knee OA



- Knee and hip OA rank 13th globally for Years Living with a Disability +56% (2000 → 2016)

US Lifetime costs of \$140k/person

- US Economic costs = \$486b (2014)
  - Direct Medical Costs \$373b
  - Indirect Costs \$113b

# Investment Risks

Japan Deal Completion

AGC Exclusive Manufacture Contract Termination

Competition

Meeting Phase 2 End Points

Risk Factors

Liquidity Risk


# Proforma Consolidated Statement of Financial Position

Consolidated Statement of Financial Position	\$'000's	30-Jun-19 <i>Unaudited</i>	Capital Raising	Proforma
<b>Current Assets</b>				
Cash and cash equivalents		255.5	3,815.1	4,070.6
Inventories		8.6	-	8.6
R&D tax incentive receivable		1,358.2	-	1,358.2
Other current assets		275.0	-	275.0
Financial asset at a mortised cost		596.2	-	596.2
<b>Total current assets</b>		<b>2,493.4</b>	<b>3,815.1</b>	<b>6,308.6</b>
<b>Non-current assets</b>				
Property, plant and equipment		153.4	-	153.4
Intangible assets		0.0	-	0.0
Investments		3.7	-	3.7
<b>Total non-current assets</b>		<b>157.1</b>	<b>0.0</b>	<b>157.1</b>
<b>Total assets</b>		<b>2,650.6</b>	<b>3,815.1</b>	<b>6,465.7</b>
<b>Current liabilities</b>				
Trade and other payables		1,055.9	-	1,055.9
Provisions		352.7	-	352.7
Other current liabilities		3,780.0	(1,400.0)	2,380.0
Contract liabilities		3,564.3	-	3,564.3
<b>Total current liabilities</b>		<b>8,752.9</b>	<b>(1,400.0)</b>	<b>7,352.9</b>
<b>Non-current liabilities</b>				
Provisions		175.4	-	175.4
<b>Total non-current liabilities</b>		<b>175.4</b>	<b>0.0</b>	<b>175.4</b>
<b>Total liabilities</b>		<b>8,928.3</b>	<b>(1,400.0)</b>	<b>7,528.3</b>
<b>Net assets</b>		<b>(6,277.8)</b>	<b>5,215.1</b>	<b>(1,062.6)</b>
<b>Equity</b>				
Issued capital		31,076.8	5,215.1	36,292.0
Accumulated losses		(37,766.6)	-	(37,766.6)
Reserves		412.1	-	412.1
<b>Total equity</b>		<b>(6,277.8)</b>	<b>5,215.1</b>	<b>(1,062.6)</b>

The Proforma Consolidated Statement of Financial Position (Balance Sheet) is based upon the unaudited financial statements as at 30 June 2019 adjusted for the effect of the capital raising.

The consequence of the raise is that share capital increases by \$5.2 million, represented by new capital of \$4.1 million and conversion of \$1.4 million (56%) of the Director loan, partially offset by the associated capitalised costs anticipated at \$0.3 million.

# Contact



Sandra McIntosh  
Company Secretary and Investor Relations  
P: +61 2 9499 8010  
M: +61 450 253 059  
E: [sandra.mcintosh@regeneus.com.au](mailto:sandra.mcintosh@regeneus.com.au)